A process for the preparation of carbonyl compounds starting from olefins is described, comprising the oxidative scission reaction of one or more carbon- carbon double bonds, where electron-poor double bonds and terminal bonds which do not have neighbouring functional groups capable of donate electronic density are excluded, wherein such reaction is carried out by means of an advanced oxidation process, in the presence of at least one nitrogen-containing additive and at least one advanced oxidation agent, the advanced oxidation process being a chemical treatment which in a reaction produces oxidation of chemical compounds through the generation of active radical species.
C07B 41/06 - Formation ou introduction de groupes fonctionnels contenant de l'oxygène de groupes carbonyle
C07C 45/28 - Préparation de composés comportant des groupes C=O liés uniquement à des atomes de carbone ou d'hydrogènePréparation des chélates de ces composés par oxydation de restes —CHx
C07C 49/258 - Composés non saturés comportant des groupes cétone liés à des atomes de carbone acycliques contenant des groupes —CHO
2.
PEPTIDES FOR THE PREPARATION OF VACCINES AGAINST SARS-COV-2
The present invention relates to epitope peptides of CD8+ cells from SARS-CoV-2 having a maximum length of 14 amino acids and comprising an amino acid sequence selected from SEQ ID NO. 1-18. There are further provided nucleic acids encoding such peptides, recombinant vectors comprising such nucleic acid sequences, a host cell comprising such nucleic acid sequences, an immunogenic composition comprising such peptides or such nucleic acid sequences. Finally, there is provided the use of the peptides for immunizing a subject against SARS-CoV-2 and in diagnosing SARS-CoV-2 infection.
A distinctly anti-vibration handle grip, in particular for motorcycles, allows a significant reduction in the transmitted vibrations, eased by a better adaptation of the handle grip to the anthropometric features of the driver's hand, and comprises: an internal cylinder (4), which is fitted on the receiving stem; and an external casing (5), enclosing said internal cylinder ((44)) from a proximal end (2) to a distal end (3) of the anti- vibration handle grip (1), and which is connected to said internal cylinder (4) by means of a sequence of circumferential junctions (6), forming a corresponding sequence of grooves (7) on the external surface of the external casing (5) and respective inner tubes (8), formed by the empty space between external casing (5) and internal cylinder (4), between each one of said grooves (7), wherein the distances between the adjacent grooves depend upon the anthropometric measurements of the user's hand.
B25F 5/00 - Détails ou parties constitutives d'outils portatifs à moteur sans relation spécifique avec les opérations exécutées et non prévus ailleurs
F16F 15/08 - Suppression des vibrations dans les systèmes non rotatifs, p. ex. dans des systèmes alternatifsSuppression des vibrations dans les systèmes rotatifs par l'utilisation d'organes ne se déplaçant pas avec le système rotatif utilisant des moyens élastiques avec ressorts en caoutchouc
4.
NANOSYSTEM FOR DIAGNOSIS AND PHOTOTHERMAL TREATMENT OF TUMORS
The invention relates to a nanosystem for the diagnosis, image-guided treatment of tumors and monitoring of the tumor microenvironment. The nanosystem is a contrast agent comprising a polymer shell based on a hyaluronic acid nanogel, super-paramagnetic iron oxide nanoparticles (SPIONs) and carbon nanoparticles (CDs).
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
A61K 41/00 - Préparations médicinales obtenues par traitement de substances par énergie ondulatoire ou par rayonnement corpusculaire
A61K 47/61 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique le composé organique macromoléculaire étant un polysaccharide ou l’un de ses dérivés
A61K 49/18 - Préparations de contraste pour la résonance magnétique nucléaire [RMN]Préparations de contraste pour l'imagerie par résonance magnétique [IRM] caractérisées par un aspect physique particulier, p. ex. émulsions, microcapsules, liposomes
B82Y 5/00 - Nanobiotechnologie ou nanomédecine, p. ex. génie protéique ou administration de médicaments
B82Y 15/00 - Nanotechnologie pour l’interaction, la détection ou l'actionnement, p. ex. points quantiques comme marqueurs en dosages protéiques ou moteurs moléculaires
C08B 37/08 - ChitineSulfate de chondroïtineAcide hyaluroniqueLeurs dérivés
C23C 22/60 - Traitement chimique de surface de matériaux métalliques par réaction de la surface avec un milieu réactif laissant des produits de réaction du matériau de la surface dans le revêtement, p. ex. revêtement par conversion, passivation des métaux au moyen de solutions aqueuses au moyen de solutions aqueuses alcalines d'un pH > 8
A process is described for covering magnesium alloys with a coating based on magnesium phosphates, magnesium carbonates and hydroxyapatite which sequentially comprises an anodization step under galvanostatic conditions followed by an annealing step and a biocompatibilization step with precipitation of a hydroxyapatite layer; the coated magnesium alloys obtained can be used for the preparation of biomedical devices.
FONDAZIONE PER LA RICERCA SULLA FIBROSI CISTICA—ONLUS (Italie)
Inventeur(s)
Pibiri, Ivana
Pace, Andrea
Tutone, Marco
Lentini, Laura
Melfi, Raffaella
Di Leonardo, Aldo
Abrégé
Are disclosed oxadiazole derivatives, their use as medicaments and in particular for the treatment of diseases associated with the presence of a nonsense mutation in the gene or a premature stop codon in the mRNA, pharmaceutical formulation comprising said oxadiazole derivatives and prodrug or mixture thereof and the methods for the preparation of said Oxadiazole derivatives.
C07D 271/07 - Oxadiazoles-1, 2, 4Oxadiazoles-1, 2, 4 hydrogénés avec des atomes d'oxygène, de soufre ou d'azote, liés directement aux atomes de carbone du cycle, les atomes d'azote ne faisant pas partie d'un radical nitro
A method to be used for the monitoring of vegetation surfaces is described, which includes the use of a device for measuring the spectral reflectance of vegetation using images acquired with a lightening system based on visible and infrared monoband LEDs and including devignetting, image cropping, radiometric calibration procedures and calculation of reflectance values and vegetation indices.
G01N 21/25 - CouleurPropriétés spectrales, c.-à-d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes
G01J 3/02 - SpectrométrieSpectrophotométrieMonochromateursMesure de la couleur Parties constitutives
G01N 21/31 - CouleurPropriétés spectrales, c.-à-d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p. ex. spectrométrie d'absorption atomique
The present invention relates to heterocyclic nitrogen compounds, use thereof as a medicament and pharmaceutical compositions thereof. Furthermore, the invention provides combinations of compounds of general formula (I) with therapeutic agents, such as correctors, potentiators and amplifiers of dysfunctional proteins.
A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
The present invention relates to heterocyclic nitrogen compounds, use thereof as a medicament and pharmaceutical compositions thereof. Furthermore, the invention provides combinations of compounds of general formula (I) with therapeutic agents, such as correctors, potentiators and amplifiers of dysfunctional proteins.
A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
14.
PROCESS FOR SYNTHESIS OF EXOSOMES CONTAINING THE HEAT SHOCK PROTEIN HSP60 AND THEIR USE FOR THE TREATMENT OF MUSCULAR ATROPHY AND CACHEXIA
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
INSERM INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (France)
UNIVERSITÀ TELEMATICA ECAMPUS (Italie)
UNIVERSITÀ DEGLI STUDI DI ROMA “LA SAPIENZA” (Italie)
Inventeur(s)
Gasco, Paolo
Multhoff, Gabriele
Adamo, Sergio
Coletti, Dario
Macaluso, Filippo
D'Amico, Daniela
Trovato, Eleonora
Farina, Felicia
Cappello, Francesco
Campanella, Claudia
Marino Gammazza, Antonella
Barone, Rosario
Abrégé
A process for the in vitro preparation of vesicles containing as an active ingredient the heat shock protein of 60 kDa Hsp60 and the use of vesicles as a medicament in particular for the treatment of muscular atrophy or sarcopenia and of cachexia is described.
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
15.
COMPOSITION FOR USE IN THE FINISHING, PRESERVATION, RESTORATION OF MANUFACTURES
UNIVERSITA' DEGLI STUDI DI ROMA "LA SAPIENZA" (Italie)
UNIVERSITA' DEGLI STUDI DI PALERMO (Italie)
Inventeur(s)
Bianco, Armandodoriano
Serafini, Ilaria
Cavallaro, Giuseppe
Lazzara, Giuseppe
Abrégé
An aqueous composition comprising chitosan and fibroin nanoparticles, with a diameter equal or lower than 140 nm, and an acid agent, with pH equal or lower than 6, and viscosity equal or lower than 3.5 kg × m−1× s−1 measured at 25.0±0.1 °C, kit and method for finishing and/or preservation and/or restoration and/or renovation and/or repairing and/or consolidation of manufactures, in particular ancient manufactures are disclosed.
FONDAZIONE PER LA RICERCA SULLA FIBROSI CISTICA - ONLUS (Italie)
Inventeur(s)
Pibiri, Ivana
Pace, Andrea
Tutone, Marco
Lentini, Laura
Melfi, Raffaella
Di Leonardo, Aldo
Abrégé
Are disclosed oxadiazole derivatives, their use as medicaments and in particular for the treatment of diseases associated with the presence of a nonsense mutation in the gene or a premature stop codon in the mRNA, pharmaceutical formulation comprising said oxadiazole derivatives and prodrug or mixture thereof and the methods for the preparation of said Oxadiazole derivatives.
C07D 413/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 271/07 - Oxadiazoles-1, 2, 4Oxadiazoles-1, 2, 4 hydrogénés avec des atomes d'oxygène, de soufre ou d'azote, liés directement aux atomes de carbone du cycle, les atomes d'azote ne faisant pas partie d'un radical nitro
A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
A connecting node structure (1), capable of acting as constraint to be arranged at the bottom of pillars and as connection between pillars and beams constituting a structure made of steel, that is a strut assembly or a frame, allows to obtain a frame made of steel with stiffness and resistance features independent therebetween and on this regard it comprises: a first flat connecting plate (2), apt to be connected to a connecting end of a first frame beam (121), and a second connecting plate (3), apt to be connected to a connecting end of a second frame beam (122), said flat connecting plates (2, 3) perpendicular like a L having a mutual spatial relation depending upon the shape and position of said connecting ends and one of their respective flat connecting backplates (125, 126) which is adhered to said first and second flat connecting plate (2, 3); and one or more stiff connecting elements (5, 8, 11) implemented by a L-like profile, interposed between said first and second flat connecting plate (2, 3), implementing a stiff connection therebetween and which have as a whole a stiff resistance limit, in terms of bending moment, lower than that of the beams (121, 122) which are connected, therebeyond said stiff connecting elements (5, 8, 11) deform plastically.
E04B 1/24 - Structures comportant des éléments porteurs allongés, p. ex. colonnes, poutres, ossatures les pièces porteuses étant métalliques
E04H 9/02 - Bâtiments, groupes de bâtiments ou abris conçus pour résister à des situations extérieures anormales, p. ex. à des bombardements, à des séismes ou à des climats extrêmes, ou pour se protéger de ces situations résistant aux séismes ou à l'effondrement du sol
18.
IN VITRO CELLULAR CO-CULTURE METHOD TO INDUCE IMMUNOLOGICAL TOLERANCE
An in vitro method able to modulate peripheral blood mononuclear cells of patients with auto-immune organ-specific diseases is described. The protocol makes auto-reactive lymphocytes tolerogenic through a process of re-education in recognition of self-antigen after co-culture with heterologous and/or autologous fibroblast limbal stem cells.
A61K 35/15 - Cellules de la lignée des myéloïdes, p. ex. granulocytes, basophiles, éosinophiles, neutrophiles, leucocytes, monocytes, macrophages ou mastocytesCellules précurseurs myéloïdesCellules présentatrices d’antigène, p. ex. cellules dendritiques
19.
4,5,6,9-TETRAHYDROPYRROLO[2',3':3,4]CYCLOHEPTA[1,2-D] ISOXAZOLE, PROCESS FOR THEIR PRODUCTION AND THEIR USES AS ANTITUMOR AGENTS
The present invention concerns the synthesis of compounds bearing the pyrrolo[2',3':3,4]cyclohepta[1,2-d]isoxazole structure, and their use for the treatment of pathologies having hyperproliferative features included those having neoplastic nature.
The present invention relates to the obtainment of vegetable products showing pharmacological activity and their therapeutic use. In particular the invention refers to vesicles of nanometric dimensions obtained from the juice of plants of the family Rutaceae.
The present invention relates to a specific inhibitor for a human microRNA, for the use in the therapeutic treatment of aberrant angiogenesis and of diseases associated with aberrant angiogenesis and pharmaceutical compositions that comprise it.
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
A61K 31/712 - Acides nucléiques ou oligonucléotides ayant des sucres modifiés, c.-à-d. autres que le ribose ou le 2'-désoxyribose
A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
22.
Method to produce hyaluronic acid functionalized derivatives and formation of hydrogels
2—R.
The group inserted by nucleophilic substitution can contain in another its terminal portion a further nucleophilic functional group, in a way to be easily exploitable to further chemical functionalizations, such as an example to obtain the methacrylation of HA functional groups, to obtain photocrosslinkable derivatives.
Both direct derivatives of the proposed process and those obtained by the further functionalization can be employed to produce hydrogels.
The present invention places in the field of managing energy, in particular coming from renewable or environmental energy sources, harvester sources, typically not correlated sources and it proposes a system for supplying electrical energy to a load, from a plurality of energy sources, together with a method for managing such system, which manages the power transfer from the plurality of input sources towards the loading device.
Synthesis apparatus on catalytic bed and separation of synthetic products comprising a gaseous phase and two liquid phases, a heavier liquid phase and the other liquid phase lighter, the apparatus comprising - a synthesis module (M1 ) comprising a first tube (1) provided with an opening at one end and closed at a second end by a mesh (7), the first tube (1) being adapted to contain a catalytic bed (6) therein; - and a separation module (M2) for separating the two liquid phases and the gaseous phase originating from the synthesis module (M1), comprising a second tube (V) arranged adjacent to the second end of the first tube (1), communicating therewith at a first end thereof, and having, at a second end thereof, a first closure element (13) that is provided with a through hole.
B01J 8/04 - Procédés chimiques ou physiques en général, conduits en présence de fluides et de particules solidesAppareillage pour de tels procédés avec des particules immobiles, p. ex. dans des lits fixes le fluide passant successivement à travers plusieurs lits
Object of the present invention is a method and the related production technology for the manufacturing of multifunctional suture threads with antimicrobial and/or antibiotic and/or cicatrizing properties that can be modulated as a function of the manufacturing conditions. The threads can display single properties or multiple properties among those described above. In particular, it was build up a technology that consider the melt incorporation of an antimicrobial and/or antibiotic and/or cicatrizing agent during the preparation of the suture threads. The spinning process is inline with the extrusion and by modulating the amount of agent, the drawing conditions (isothermal and non-isothermal), it is possible to regulate the final diameter, the mechanical resistance and the release of the necessary amount of agent over the space (i.e. locally in the proximity of the filament) and over the time (i.e. regulating the duration of the antimicrobial and/or antibiotic and/or cicatrizing activity) according to a precise linear function.
UNIVERSITA' DEGLI STUDI MAGNA GRAECIA DI CATANZARO (Italie)
UNIVERSITA' DEGLI STUDI DI PALERMO (Italie)
Inventeur(s)
Fresta, Massimo
Giammona, Gaetano
Cavallaro, Gennara
Licciardi, Mariano
Paolino, Donatella
Abrégé
The present invention describes biphosphonate-polymer conjugates, where the polymer has a poly-hydroxy-aspartamide backbone structure, able to accumulate into bone tissue and as such useable as carriers for the targeting to the bones of active agents, chemically linked or physically entrapped into biphosphonate- polymer conjugate, or as macromolecular prodrugs also able to accumulate into bone tissue and to release the biphosphonates.
C08G 69/10 - Polyamides dérivés, soit des acides amino-carboxyliques, soit de polyamines et d'acides polycarboxyliques dérivés d'acides aminocarboxyliques d'acides alpha-aminocarboxyliques
C08L 77/04 - Polyamides dérivés des acides alpha-aminocarboxyliques
A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament
A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases
C08G 69/48 - Polymères modifiés par post-traitement chimique
The wind turbine has a central axis that supports pairs of blades offset by 90°, each pair is integral with a single supporting shaft able to rotate relative to the central axis of the turbine owing to coupling by means of bearings. The pairs of blades are orientated automatically in order to present the maximum possible surface area of the blades to the wind when they move in the direction of the wind, at the same time minimizing the surface area of the blades when they move against the wind. The large surface exposed to the action of the wind is not opposed by a braking action due to the blades moving against the wind, which produces a very high torque on the central axis. The turbine operates with the wind blowing from any direction and is able to start moving even in the presence of very light winds.
The present invention describes a feedstuff composition for aquaculture of echinoids or herbivorous or omnivorous species, said feedstuff formulation includes egg albumen and ground vegetal material of the genus Lactuca as its main ingredients. The composition of the invention is cooked in order to obtain a cookie having a consistency suitable for being preserved in water. The feed was shown to possess properties that guarantee maintenance of the organoleptic characteristics of the animal reared, while ensuring a nutrient content that can generate much greater quantities of edible tissue with an average ratio of about 2- 5 to 1 with respect to wild organisms.
Production of paramagnetic and phosphorescent nanoprobes, obtainable starting from nanometric silica particles by methods of synthesis and enrichment with O2 following suitable thermal treatments in a controlled environment. The nanoprobes thus obtained display emission in the near infrared (NIR), are excitable in the visible and in the NIR, and are characterized by a lifetime of the order of one second. These nanoprobes have considerable scientific and commercial potential in the market of the confocal spectroscopy for bio-imaging and in the market of the medical pharmaceutical applications of drug labelling and drug delivery.
2—R. The group inserted by nucleophilic substitution can contain in another its terminal portion a further nucleophilic functional group, in a way to be easily exploitable to further chemical functionalizations, such as an example to obtain the methacrylation of HA functional groups, to obtain photocrosslinkable derivatives. Both direct derivatives of the proposed process and those obtained by the further functionalization can be employed to produce hydrogels.
The invention describes a four-step differentiation protocol which efficiently directs LSCs, in particular a fibroblast-like LSC population characterized by the expression of several pluripotent stem cell markers and exhibiting self-renewal ability, towards the endocrine cell fate, eventually leading to production of pancreatic hormone-expressing cells. In addition, LSC-derived insulin-producing cells obtained according to the invention are fully functional as demonstrated by the ability to secrete C-peptide in response to glucose and other stimuli, similar to beta cells. Thus they possess distinctive features which make them optimal candidates for potential therapeutic application in diabetes.
The present invention concerns the synthesis of new analogs of angelicins, pyrrolo[3,2-h]quinoline, for the treatment of pathologies having hyperproliferative character included those having neoplastic nature. The treatment is based on the combined action of pyrrolo[3,2-h]quinolines and UV-A light, through a clinical approach defined as PUVA (psoralen+UVA light). The most important feature of these compounds is that they exert their remarkable phototoxicity without any DNA damage, which is the main origin of the side effects of the PUVA therapy.
A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
A method is described which enables the production of embryonic pluripotent cancer stem cells following treatment of cancer cells with PARP inhibitors for prolonged periods; also described are the cells obtained by means of the aforesaid treatment applied to human osteosarcoma cells, and their use.
In this invention a two steps procedure is described useful to insert functional groups to the hyaluronic acid (HA), through the formation, in organic solvent, of a particular active group on hydroxyl groups of HA and subsequent substitution, on the inserted active group, with a pendant portion containing at least in its terminal portion a nucleophilic functional group, NH2-R. The group inserted by nucleophilic substitution can contain in another its terminal portion a further nucleophilic functional group, in a way to be easily exploitable to further chemical functionalizations, such as an example to obtain the methacrylation of HA functional groups, to obtain photocrosslinkable derivatives. Both direct derivatives of the proposed process and those obtained by the further functionalization can be employed to produce hydrogels.
In this invention a two steps procedure is described useful to insert functional groups to the hyaluronic acid (HA), through the formation, in organic solvent, of a particular active group on hydroxyl groups of HA and subsequent substitution, on the inserted active group, with a pendant portion containing at least in its terminal portion a nucleophilic functional group, NH2-R. The group inserted by nucleophilic substitution can contain in another its terminal portion a further nucleophilic functional group, in a way to be easily exploitable to further chemical functionalizations, such as an example to obtain the methacrylation of HA functional groups, to obtain photocrosslinkable derivatives. Both direct derivatives of the proposed process and those obtained by the further functionalization can be employed to produce hydrogels.
Organotin(IV) compounds with N-acetylcysteine having the general formula (1 ) o (2): wherein: R1, R2 and R3 are each independently selected from the group consisting of : H, an alkyl, alkoxyl, alkenyl or alkynyl group with up to 12 carbon atoms, an isocyclic or heterocyclic aromatic or aralkyl group with up to 12 carbon atoms, and they are preferably chosen from methyl, ethyl, butyl or phenyl, are synthetized by simple procedures from commercial products, and are active as anticancer agents. In particular, the Bu2Sn-N-acetylcysteinate derivative was found to have a potent and selective anticancer activity in vitro against several cancer cell lines.
A tool in support of oral implantology, which allows drills to run on the jaw, reducing associated problems such as perforation of the bony wall, with the ability to orient the instrument in two directions and secure it to the jaw structure by defining the correct position of the drill-axis and maintaining them during the drilling itself, the tool including: a support member, which provides a driving help for implantology; a locking system to link to the bone site, presenting the various elements of the block at the opposite ends of the support, which is able to rotate relative to at least one respective axis A, B and can be locked in a desired position, and a system to scan the location of a bone site, associated with that support member, instead of a fixed axis.
The invention concerns delivery systems for the release of active ingredients, specifically peptides and proteins, by means of their incorporation in nanoparticles, nano-aggregates or complexes based on suitably derivatized synthetic polyaminoacids, consisting of copolymers with a polyaspartamide backbone (specifically, alpha.beta-poly-hydroxyethyl-aspartamide or PHEA) to which hydrophobic functionalities, ioπisable functionalities and thiol functional- ities in side chains are covalently linked, each individually or in combination with each other. Such polymer systems are proposed to release peptide drugs or pro¬ teins, such as insulin, from oral dosage forms in an effective manner, and in order to increase the physicochemicai stability of proteins in liquid or solid pharmaceutical dosage forms.
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
40.
METHOD FOR THE GENOTYPING OF HIV-1 AND RELEVANT DIAGNOSTIC KITS FOR THE DETECTION OF DRUG RESISTANCES
The invention concerns a method for HIV-1 genotyping by gp41-env gene sequencing for the detection of mutations associated to resistances to fusion inhibitors antiretroviral drugs and related diagnostic kit.
C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages
41.
MEASUREMENT METHOD FOR MEASURING THE PEAK FLOW DISCHARGES AND THE CHANNEL BED ROUGHNESS IN A NATURAL OR ARTIFICIAL WATER COURSE AND RELATED SYSTEM
Measurement system for measuring peak flow discharges comprising at least two water level measurement instruments, including radar sensors or other suitable sensors placed outside the stream flow, located at suitable distance from each other in correspondence with respective channel sections; the shape of the channel between the sections varying gradually or, however, with known law. The synchronous acquisition of the water levels allows, by means of a numerical analysis of the unsteady-state process, to compute both the peak flow discharge and the average bed roughness at the flood time.
G01F 1/00 - Mesure du débit volumétrique ou du débit massique d'un fluide ou d'un matériau solide fluent, dans laquelle le fluide passe à travers un compteur par un écoulement continu
G01F 23/00 - Indication ou mesure du niveau des liquides ou des matériaux solides fluents, p. ex. indication en fonction du volume ou indication au moyen d'un signal d'alarme
G01F 23/28 - Indication ou mesure du niveau des liquides ou des matériaux solides fluents, p. ex. indication en fonction du volume ou indication au moyen d'un signal d'alarme en mesurant des variables physiques autres que les dimensions linéaires, la pression ou le poids, selon le niveau à mesurer, p. ex. par la différence de transfert de chaleur de vapeur ou d'eau en mesurant les variations des paramètres des ondes électromagnétiques ou acoustiques, appliquées directement au liquide ou au matériau solide fluent
E02B 3/00 - Ouvrages relatifs au contrôle ou à l'utilisation des cours d'eau, rivières, côtes ou autres emplacements maritimesÉtanchements ou joints pour travaux de génie civil en général
Non invasive method used to detect a 'sonic imprint' of three-dimensional objects, particularly suitable for the identification and monitoring of artworks, consisting in acquiring the vibrations caused by a source of elastic waves and using a set of detectors fixed in various predetermined points of the external surface of the object. An apparatus, cheap and simple to utilize, suitable to execute this method, is also described.
New isoindolo[2,1-a]quinoxaline derivatives of general formula (1 ), wherein R represents H or OH and R5 represents H or CN, have been prepared with simple procedures starting from known intermediates and resulted to posses potent in vitro antitumor activity against a panel of about 60 different human tumor cell lines belonging to several kinds of tumors, both hematological and solid. Preparations containing such derivatives as active ingredients are proposed as drugs to be employed in cancer therapy both alone and in combination with other chemotherapeutics.
This invention relates to nanoparticles consisting of riluzole trapped in lipids, and their use to prepare medicinal products for the treatment of Amyotrophic Lateral Sclerosis and Multiple Sclerosis.
brevets
